Global Alpha And Beta Emitters Based Radiopharmaceuticals Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
USD
801.45 Million
USD
1,769.20 Million
2024
2032
 예측 기간 |
2025 –2032 |
 시장 규모(기준 연도) |
USD 801.45 Million |
 시장 규모(예측 연도) |
USD 1,769.20 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
|
동위원소(베타 및 알파 방출체), 공급원(반응기 생성 동위원소, 발전기 생성 동위원소 및 기타), 치료적 적용(종양학 및 기타), 벡터 유형(소분자 리간드, 펩타이드, 단일클론 항체 및 기타), 최종 사용자(병원, 방사성 약국 및 연구소)별 글로벌 알파 및 베타 방출체 기반 방사성 의약품 시장 세분화 - 2032년까지의 산업 동향 및 예측
알파 및 베타 방출체 기반 방사성 의약품 시장 규모
- 글로벌 알파 및 베타 방출체 기반 방사성 의약품 시장 규모는 2024년에 8억 145만 달러 로 평가되었으며 예측 기간 동안 10.4%의 CAGR 로 2032년까지 17억 6,920만 달러에 도달할 것으로 예상됩니다 .
- 시장 성장은 주로 표적 알파 및 베타 치료의 효능 증가에 의해 촉진됩니다.
- 더욱이, 개인 맞춤 의료 분야에서 테라노스틱스(Theranostics)의 도입이 증가하고 있습니다. 이러한 융합 요인들은 알파 및 베타 방출체 기반 방사성 의약품 솔루션의 도입을 가속화하여 업계 성장을 크게 촉진하고 있습니다.
알파 및 베타 방출체 기반 방사성 의약품 시장 분석
- 알파 및 베타 방출체 기반 방사성 의약품은 특히 종양학 및 핵의학 분야에서 표적 치료의 정확성으로 점점 더 인정받고 있으며, 최소한의 부작용으로 효과적인 진단 및 치료 옵션을 제공합니다.
- 전 세계적으로 암 발병률이 증가하고 개인화된 의학에 대한 인식이 높아지고 방사성 약학 기술이 발전함에 따라 알파 및 베타 방출체 기반 방사성 약학에 대한 글로벌 수요가 증가하고 있습니다.
- 북미는 첨단 의료 인프라, 광범위한 R&D 활동, 새로운 치료 기술의 조기 도입에 힘입어 2025년 매출의 약 42.59%를 차지하며 글로벌 알파 및 베타 방출체 기반 방사성 의약품 시장에서 상당한 점유율을 차지하고 있습니다.
- 북미 지역은 의료 인프라 확장, 암 유병률 증가, 의료 개선을 위한 정부 이니셔티브에 힘입어 예측 기간 동안 알파 및 베타 방출체 기반 방사성 의약품 시장에서 가장 빠르게 성장할 것으로 예상됩니다.
- 베타 방출체 부문은 표적 알파 치료(TAT)에서의 높은 효능, 향상된 환자 결과, 암 치료를 위한 액티늄-225 및 라듐-223과 같은 알파 방출 동위 원소에 초점을 맞춘 연구 증가에 힘입어 2025년에 84.78%의 시장 점유율을 기록하며 시장을 지배할 것으로 예상됩니다.
보고서 범위 및 알파 및 베타 방출기 기반 방사성 의약품 시장 세분화
|
속성 |
알파 및 베타 방출체 기반 방사성 의약품 주요 시장 통찰력 |
|
다루는 세그먼트 |
|
|
포함 국가 |
북아메리카
아시아 태평양
유럽
남아메리카
중동 및 아프리카
|
|
주요 시장 참여자 |
|
|
시장 기회 |
|
|
부가가치 데이터 정보 세트 |
Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 적용 범위, 주요 기업 등 시장 시나리오에 대한 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함됩니다. |
알파 및 베타 방출체 기반 방사성 의약품 시장 동향
“ 표적 알파 및 베타 치료의 효능 증가 ”
- 글로벌 알파 및 베타 방출체 기반 방사성 의약품 시장의 주요 원동력은 신경내분비 종양 및 전이성 거세 저항성 전립선암(mCRPC)과 같은 진행성 암 치료에 효과가 입증되어 표적 방사성 핵종 치료법의 임상적 채택이 증가하고 있다는 것입니다.
- 예를 들어, 2023년 5월 NCBI에 발표된 논문에 따르면, 승인된 [177Lu]Lu-PSMA-617 요법(6주마다 7.4 GBq/주기, 최대 6주기)은 실제 사용에서 강력한 안전성과 항종양 효능을 보였으며, 용량(6~9.3 GBq)과 치료 간격(4~10주)이 유연했습니다. 이러한 일관된 임상적 성과는 의사의 신뢰를 높이고 시장 도입을 가속화합니다.
- Lu-177과 같은 방사성 의약품은 특히 펩타이드 수용체 방사성 핵종 치료(PRRT)에 사용될 때 신경내분비 종양 치료에 놀라운 성공을 거두었으며 건강한 조직을 보존하면서 종양 부위에 강력한 베타 방사선을 직접 전달하여 결과가 개선되고 수요가 증가했습니다.
- Ac-225와 같은 알파 방출 동위원소의 기술적 발전과 임상적 검증은 시장 성장을 더욱 촉진했습니다. Ac-225는 기존 치료법에 내성을 가진 전립선암 세포를 표적으로 삼는 데 매우 효과적이며, 부작용은 최소화하고 치료 효과는 강력합니다.
알파 및 베타 방출체 기반 방사성 의약품 시장 동향
운전사
"개인 맞춤 의학에서 테라노스틱스 도입 증가"
- 루테튬-177(Lu-177)과 테르븀-161(Tb-161)과 같은 치료진단용 알파 및 베타 방출 방사성의약품의 채택 증가는 글로벌 방사성의약품 시장을 견인하는 주요 동력입니다. 단일 임상 워크플로우에서 진단 영상과 표적 치료를 결합하여, 이러한 제제는 환자 맞춤형 정밀 치료를 제공하여 치료 결과를 개선하고 치료 계획을 간소화합니다.
- 예를 들어, 2023년 7월 NCBI에 발표된 한 리뷰에서는 Lu-177 기반 치료진단 요법(예: 신경내분비종양에 대한 ¹⁷⁷Lu-DOTATATE 및 전립선암에 대한 ¹⁷⁷Lu-PSMA)의 임상적 사용이 증가하고 있다고 보고했습니다. 이러한 약물에 대한 FDA 승인은 안전성과 효능을 검증하여 도입을 가속화하고, 진단-치료 조합의 강력한 시너지 효과를 강조했습니다.
- 종양학자와 핵의학 전문가들 사이에서 치료진단 접근 방식과 관련된 워크플로우 효율성, 치료 정확도 및 독성 감소에 대한 인식이 높아지면서 임상의들이 개인화된 암 관리를 위한 신뢰할 수 있는 도구를 찾고 있기 때문에 수요가 증가하고 있습니다.
- 또한, 의료 시스템이 생존율 향상 및 비용 통제를 위한 압박이 커지면서 Lu-177 및 Tb-161과 같은 통합 영상 치료 솔루션은 치료 시간을 단축하고 비효과적인 개입을 피하며 삶의 질을 향상시켜 가치 제안을 강화합니다.
- Tb-149, Tb-152/155, Ac-225와 같은 차세대 동위원소에 대한 지속적인 R&D와 더불어 정밀 종양학에 대한 선호도가 높아지면서 치료진단 방사성 의약품은 현대 암 치료의 초석이자 글로벌 시장의 핵심 성장 동력으로 자리 잡았습니다.
제지/도전
“ 짧은 동위원소 반감기로 인한 공급망 및 확장성 문제 ”
- 납-212(~10.6시간)와 같은 방사성 핵종의 짧은 반감기는 주요 물류 및 운영상의 장애물을 야기합니다. 생산은 처리 시설 근처에서 이루어져야 하며 운송 창구는 몇 시간밖에 되지 않으며 고도로 조정된 "적시 공급" 공급망이 필요합니다. 이는 집합적으로 대규모 제조 및 시장 도달 범위를 제한합니다.
- 예를 들어, 2025년 4월 LEK Consulting은 Pb-212의 10.6시간 반감기가 분산형, 환자 근처 생산 및 현장 발전기 인프라를 강제로 강제하여 규모의 경제성을 제한하고 유통 물류를 복잡하게 만든다고 지적했습니다.
- 또한 Pb-212(및 기타 단명 동위 원소)를 추출하는 데 필요한 복잡한 생성 시스템은 규정 준수, 방사선 안전 요구 사항 및 자본 지출을 늘려 병원 및 방사선 약국에서 광범위한 배포를 어렵게 만듭니다.
- 소형 발전기, 더 빠른 정제 방법 및 지역 생산 허브의 발전으로 결국 이러한 압박이 완화될 수 있지만, 수명이 짧은 동위 원소의 근본적인 시간 민감성은 방사성 의약품 시장의 광범위한 채택 및 성장을 크게 제한하는 요인으로 남아 있습니다.
알파 및 베타 방출체 기반 방사성 의약품 시장 범위
시장은 동위원소, 공급원, 치료적 적용, 벡터 유형 및 최종 사용자를 기준으로 세분화됩니다.
- 동위원소에 의해
동위원소 유형에 따라 시장은 베타 방출체와 알파 방출체로 구분됩니다. 루테튬-177(Lu-177) 및 이트륨-90(Y-90)과 같은 동위원소가 신경내분비종양, 간암, 전립선암 치료에 널리 임상적으로 채택됨에 따라, 2025년에는 베타 방출체 부문이 84.78%의 시장 점유율을 차지하며 시장을 장악할 것으로 예상됩니다. 베타 방출체는 비교적 긴 반감기, 확립된 안전성 프로파일, 그리고 기존 임상 워크플로우와의 호환성 때문에 선호됩니다.
베타 방출체 분야는 2025년부터 2032년까지 9.1%의 가장 빠른 성장률을 기록할 것으로 예상되는데, 이는 첨단 암 치료에서 액티늄-225(Ac-225)와 납-212(Pb-212)의 사용 증가에 힘입은 것입니다. 알파 방출체는 높은 선형 에너지 전달(LET)과 최소한의 부수적 손상으로 더 높은 종양 사멸 효능을 제공하므로, 내성암 및 전이성 암 치료에 매우 적합합니다.
- 출처별
공급원을 기준으로 시장은 원자로 생산 동위원소, 발전기 생산 동위원소, 기타 동위원소로 구분됩니다. 2025년에는 원자로 생산 동위원소가 Lu-177과 I-131과 같은 주요 베타 방출원의 대량 공급과 폭넓은 가용성으로 시장을 주도할 것으로 예상됩니다.
그러나 원자로 생산 동위원소는 Pb-212와 Ra-223과 같이 분산형 및 환자 근접 생산이 필요한 동위원소 수요 증가에 힘입어 가장 빠르게 성장할 것으로 예상됩니다. 현장 생산 시설의 증가는 알파 치료 및 단수명 방사성 의약품에 대한 관심 증가와도 일맥상통합니다.
- 치료적 적용을 통해
치료적 적용 측면에서 시장은 종양학과 기타 분야로 구분됩니다. 2025년에는 방사성 의약품이 전립선암, 신경내분비 종양, 림프종 표적 치료에서 중추적인 역할을 수행함에 따라 종양학 분야가 시장을 장악할 것으로 예상됩니다. PSMA 표적 치료와 PRRT 기반 치료의 성공률이 높아짐에 따라 종양학 분야가 이 분야에서 주도적인 위치를 더욱 공고히 할 것입니다.
종양학 부문에는 심혈관, 내분비, 신경 질환이 포함되며, 새로운 방사성 리간드의 개발과 비종양학적 적응증으로의 확장으로 꾸준한 성장이 예상됩니다.
- 벡터 유형별
벡터 유형을 기준으로 시장은 소분자 리간드, 펩타이드, 단일클론 항체 등으로 구분됩니다. 2025년에는 소분자 리간드가 빠른 조직 침투와 PSMA 및 소마토스타틴 표적 치료에 널리 사용됨에 따라 시장 점유율이 가장 높을 것으로 예상됩니다.
소분자 리간드는 접합 기술의 발전과 향상된 종양 선택성, 긴 순환 시간, 그리고 향상된 결합 효율 덕분에 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 이러한 벡터는 특히 정밀성이 매우 중요한 알파 방출 치료법에 매우 중요합니다.
- 최종 사용자별
시장은 최종 사용자 기준으로 병원, 방사선 약국, 연구소로 세분화됩니다. 2025년에는 병원이 가장 큰 시장 점유율을 차지할 것으로 예상되는데, 이는 환자의 핵의학 접근성 향상, 치료진단 부서의 성장, 그리고 선진국의 강력한 의료보험 제도에 힘입은 것입니다.
방사성의약품, 특히 반감기가 짧은 방사성의약품의 중앙집중식 및 분산식 조제에 대한 수요 증가로 방사성의약품 분야는 빠르게 성장할 것으로 예상됩니다. 연구소들은 특히 테르븀-161과 악티늄-225와 같은 차세대 동위원소 개발 및 혁신과 임상 시험에서 중요한 역할을 계속 수행할 것입니다.
알파 및 베타 방출체 기반 방사성 의약품 시장 지역 분석
- 북미는 2025년 42.59%의 가장 큰 수익 점유율로 알파 및 베타 방출체 기반 방사성 의약품 시장을 지배하고 있으며 2032년까지 강력한 CAGR로 확장될 것으로 예상됩니다.
- 풍부한 종양학 파이프라인, 빠른 치료진단 도입, 그리고 PET/SPECT 및 방사선약학 시설의 밀집된 네트워크가 뒷받침하고 있습니다. 이 지역의 핵의학 연구에 대한 강력한 연방 기금, 방사성 리간드 치료에 대한 유리한 보험급여, 그리고 Lu-177 및 Ac-225 생산업체들의 지속적인 투자는 탄력적인 국내 공급망을 구축하고 시장 주도권을 유지합니다.
- 미국과 캐나다와 같은 주요 경제권에서는 성숙한 동위원소 생산 인프라, 광범위한 임상 시험 활동, 공공-민간 파트너십을 활용하여 제조 규모를 확대하고 환자의 신속한 접근을 가능하게 합니다.
미국 알파 및 베타 방출체 기반 방사성 의약품 시장 통찰력
미국은 2025년 북미 매출에서 가장 큰 비중을 차지할 것으로 예상되는데, 이는 첨단 의료 생태계, FDA의 조기 승인(예: Lu-177 PSMA-617), PharmaLogic 및 SHINE과 같은 공급업체의 지속적인 용량 확장에 힘입은 것입니다.
캐나다 알파 및 베타 방출체 기반 방사성 의약품 시장 통찰력
캐나다는 새로운 사이클로트론과 반응기 업그레이드로 국내 Lu-177 생산을 지원하고, 외래 치료진단 센터 네트워크 확대로 정밀 종양학에 대한 수요 증가에 대응하면서 두 자릿수 성장을 기록했습니다.
아시아 태평양 알파 및 베타 방출체 기반 방사성 의약품 시장 통찰력
아시아 태평양 지역은 성장하는 지역으로, 암 발생률 급증, 대규모 환자 수, 그리고 정부의 적극적인 핵의학 역량 투자에 힘입어 2025년 세계 매출에서 상당한 비중을 차지할 것으로 예상됩니다. 국가 차원의 암 관리 프로그램, 사이클로트론 설비 확충, 그리고 루테늄-177(Lu-177)과 아세트산-225(Ac-225) 생산의 국산화는 이 지역의 성장 동력을 뒷받침하는 동시에, 보험급여 개선을 통해 환자의 접근성을 확대하고 있습니다. 주요 경제국인 중국, 인도, 일본, 한국은 국가 주도의 사업 및 글로벌 동위원소 공급업체와의 협력을 통해 방사성 의약품 생산을 빠르게 확대하고 있습니다.
중국 알파 및 베타 방출체 기반 방사성 의약품 시장 통찰력
중국은 국내 동위원소 자립에 대한 전략적 집중과 공급망 보안을 강화하는 합작 투자(예: IBA 양성자 치료 및 CGN과의 동위원소 협력)에 힘입어 2025년에 아시아 태평양 지역에서 가장 큰 점유율을 차지할 것입니다.
인도 알파 및 베타 방출체 기반 방사성 의약품 시장 통찰력
인도는 원자력부 프로그램 덕분에 BARC에서 토종 Lu-177 및 PSMA-리간드 생산을 확대하여 수입 의존도를 크게 줄이고 치료량을 늘린 덕분에 이 지역에서 가장 빠른 성장 속도를 기록했습니다.
한국 알파 및 베타 방출체 기반 방사성 의약품 시장 통찰력
2035년까지 방사성 의약품 수출 산업을 육성하기 위한 대한민국 과학기술부의 로드맵에는 Lu-177 국내 생산도 포함되어 있으며, 이를 통해 한국은 중기적으로 높은 성장률을 달성하고 지역 공급 허브로서의 지위를 확보할 수 있습니다.
유럽 알파 및 베타 방출체 기반 방사성 의약품 시장 통찰력
유럽은 2025년 전 세계 매출의 4분의 1(약 25%)을 차지하며, 자체 동위원소 생성과 테라노스틱의 광범위한 도입을 장려하는 엄격한 환경 및 품질 규정에 힘입어 2032년까지 꾸준한 CAGR로 성장할 것으로 예상됩니다. EU가 지원하는 연구 컨소시엄, Ac-225 및 Tb-161 화합물에 대한 범유럽적 시험, 그리고 중앙 집중형 방사성의약품의 급속한 확장은 지역 성장을 촉진하는 한편, EU의 EURATOM 프레임워크는 원자로에서 공급되는 동위원소의 공급을 확보하고 있습니다.
독일, 프랑스, 영국 등의 경제권은 치료진단 설비, GMP 생산 라인, 임상 연구 네트워크 분야에서 선두를 달리고 있습니다.
독일 알파 및 베타 방출체 기반 방사성 의약품 시장 통찰력
독일은 2025년에 유럽 매출에서 1위를 차지할 것으로 예상됩니다. 이는 핵의학 클리닉의 밀집된 네트워크, GMP Lu-177 공장에 대한 투자 인센티브, 영상 치료 센터의 지속적인 성장에 힘입은 것으로, 2024년까지 시장 가치가 3,929만 달러로 증가할 것으로 예상됩니다.
프랑스 알파 및 베타 방출체 기반 방사성 의약품 시장 통찰력
프랑스는 기후 변화에 탄력적인 의료 정책을 통해 저용량, 고효능 치료법을 장려하고, 오라노와 CEA를 중심으로 한 클러스터가 차세대 알파 방출 프로그램과 분산형 발전기 배치에 자금을 지원하면서 견고한 확장세를 보이고 있습니다.
알파 및 베타 방출체 기반 방사성 의약품 시장 점유율
알파 및 베타 방출체 기반 방사성 의약품 시장은 주로 다음을 포함한 잘 확립된 회사들이 주도하고 있습니다.
- 노바티스 AG(스위스)
- 에커트 & 지글러(독일)
- ITM Isotope Technologies 뮌헨 SE(독일)
- SHINE Technologies, LLC(미국)
- 액티늄 파마슈티컬스(미국)
- 알파 타우 메디컬(Alpha Tau Medical Ltd.) (이스라엘)
- ARICEUM THERAPEUTICS(독일)
- 바이엘 AG(독일)
- 퀴륨(미국)
- IONETIX Corporation(미국)
- 동위 원소(이스라엘)
- 란테우스(미국)
- 릴리(미국)
- 니오웨이브(미국)
- NMR(미국)
- Oncoinvent(노르웨이)
- 오라노 그룹(파리)
- Radiopharm Theranostics Limited(호주)
- 텔릭스 파마슈티컬스 리미티드(호주)
- 테르테라(네덜란드)
알파 및 베타 방출체 기반 방사성 의약품 시장의 최신 동향
- 2025년 5월, ITM 아이소토프 테크놀로지스 뮌헨 SE와 라디오팜 테라노스틱스는 비담체 첨가 루테튬-177(nca 177Lu) 공급 계약을 발표했습니다. 이 파트너십은 라디오팜의 RAD 204, RAD 202, RV01을 포함한 루테튬-177 기반 치료제 임상 개발을 지원하여, 현재 진행 중이거나 향후 진행될 임상 시험에서 고형 종양의 표적 방사성의약품 치료를 위한 고품질 동위원소 접근성을 확보할 것입니다.
- 2025년 3월, FDA는 노바티스의 플루빅토(Lu-177 비피보티드 테트라크세탄)를 PSMA 양성 전이성 거세 저항성 전립선암에 조기 사용 승인을 내렸습니다. 이 승인으로 1회 ARPI 투여 후 항암화학요법 전에 투여할 수 있게 되었습니다. 3상 PSMAfore 임상 결과에 따르면, 플루빅토는 진행 또는 사망 위험을 59% 감소시켰고, 방사선학적 무진행 생존기간(PFS) 중앙값을 두 배로 늘리는 동시에 양호한 안전성 프로파일을 유지하고 환자 접근성을 크게 확대했습니다.
- 2025년 3월, 에커트앤지글러(Eckert & Ziegler)와 아톰비 글로벌 라디오파마(AtomVie Global Radiopharma)는 비운반체 첨가 루테튬-177(Theralugand)에 대한 글로벌 공급 계약을 체결했습니다. 이 파트너십은 아톰비의 CDMO 방사성 의약품 사업에 안정적이고 고품질의 루테튬-177 공급을 보장하여 전 세계적으로 초기 단계부터 후기 단계까지의 개발을 지원하고, 양사의 방사성 의약품 혁신, 규제 준수 및 환자 중심 핵의학 솔루션 역량을 강화합니다.
- 2025년 3월, 에커트앤지글러(Eckert & Ziegler)와 액티늄 파마슈티컬스(Actinium Pharmaceuticals)는 고순도 액티늄-225(Ac-225) 공급 계약을 체결했습니다. 이 파트너십은 액티맙-A(Actimab-A) 및 AML(급성 골수성 백혈병)과 고형 종양을 표적으로 하는 기타 방사선 치료 후보 물질의 개발을 지원하는 안정적인 Ac-225 공급원을 확보하여 액티늄의 임상 파이프라인을 강화하고 정밀 방사성 의약품 치료 분야의 전 세계 동위원소 공급 문제를 해결할 것입니다.
- 2024년 5월, 노바티스 AG는 마리아나 온콜로지(Mariana Oncology)를 계약금 10억 달러와 최대 7억 5천만 달러의 마일스톤 지급금으로 인수하기로 합의했다고 발표했습니다. 이번 인수를 통해 노바티스는 소세포 폐암 치료제인 악티늄 기반 후보물질 MC-339를 포함하여 고형 종양을 타겟으로 하는 전임상 자산을 확보하여 방사성 리간드 치료제(RLT) 파이프라인을 강화하고, RLT 연구, 공급 및 혁신 역량을 강화할 수 있게 되었습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 END USER MARKET COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 PIPELINE
4.4 SUPPLY CHAIN ECOSYSTEM
4.4.1 PROMINENT COMPANIES
4.4.2 SMALL & MEDIUM SIZE COMPANIES
4.4.3 END USERS
4.5 INDUSTRY INSIGHTS:
4.5.1 MICRO AND MACRO ECONOMIC FACTORS
4.5.2 KEY PRICING STRATEGIES
4.6 MARKETED DRUG ANALYSIS
4.6.1 DRUG
4.6.1.1 BRAND NAME
4.6.1.2 GENERIC NAME
4.6.2 THERAPEUTIC INDICATION
4.6.3 PHARMACOLOGICAL CLASS OF THE DRUG
4.6.4 DRUG PRIMARY INDICATION
4.6.5 MARKET STATUS
4.6.6 MEDICATION TYPE
4.6.7 DRUG DOSAGE FORM
4.6.8 DOSAGES AVAILABILITY
4.6.9 PACKAGING TYPE
4.6.10 DRUG ROUTE OF ADMINISTRATION
4.6.11 DOSING FREQUENCY
4.6.12 DRUG INSIGHT
4.6.13 OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES
4.6.13.1 FORECAST MARKET OUTLOOK
4.6.13.2 CROSS COMPETITION
4.6.13.3 THERAPEUTIC PORTFOLIO
4.6.13.4 CURRENT DEVELOPMENT SCENARIO
4.7 HEALTHCARE TARIFFS IMPACT ANALYSIS
4.7.1 OVERVIEW
4.7.2 TARIFF STRUCTURES
4.7.2.1 GLOBAL VS. REGIONAL TARIFF STRUCTURES
4.7.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS
4.7.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS, REIMBURSEMENT POLICIES
4.7.2.4 ASIA-PACIFIC: GOVERNMENT-IMPOSED TARIFFS ON IMPORTED MEDICAL PRODUCTS
4.7.2.5 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS
4.7.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS
4.7.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS
4.7.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS
4.8 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS
4.8.1.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES
4.8.1.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE
4.8.1.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM
4.8.2 TRADE AGREEMENTS AND HEALTHCARE TARIFFS
4.8.2.1 WTO REGULATIONS ON HEALTHCARE TARIFFS
4.8.2.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN
4.8.2.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS
4.8.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY
4.8.4 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR
4.9 EPIDEMIOLOGY OVERVIEW
4.9.1 INCIDENCE OF ALL CANCERS BY GENDER
4.9.2 TREATMENT RATE
4.9.3 MORTALITY RATE
4.9.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
4.9.5 PATIENT TREATMENT SUCCESS RATES
5 REGULATORY FRAMEWORK
5.1 REGULATORY FRAMEWORK OVERVIEW FOR THE NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
5.1.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
5.1.2 REGULATORY APPROVAL PATHWAYS
5.1.3 LICENSING AND REGISTRATION
5.1.4 POST-MARKETING SURVEILLANCE
5.1.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
5.2 REGULATORY FRAMEWORK OVERVIEW FOR THE SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
5.2.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
5.2.2 REGULATORY APPROVAL PATHWAYS
5.2.3 LICENSING AND REGISTRATION
5.2.4 POST-MARKETING SURVEILLANCE
5.2.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
5.3 REGULATORY FRAMEWORK OVERVIEW FOR THE EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
5.3.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
5.3.2 REGULATORY APPROVAL PATHWAYS
5.3.3 LICENSING AND REGISTRATION
5.3.4 POST-MARKETING SURVEILLANCE
5.3.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
5.4 REGULATORY FRAMEWORK OVERVIEW FOR THE ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
5.4.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
5.4.2 REGULATORY APPROVAL PATHWAYS
5.4.3 LICENSING AND REGISTRATION
5.4.4 POST-MARKETING SURVEILLANCE
5.4.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
5.5 REGULATORY FRAMEWORK OVERVIEW FOR THE MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
5.5.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
5.5.2 REGULATORY APPROVAL PATHWAYS
5.5.3 LICENSING AND REGISTRATION
5.5.4 POST-MARKETING SURVEILLANCE
5.5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES
6.1.2 GROWING ADOPTION OF THERANOSTICS IN PERSONALIZED MEDICINE
6.1.3 RISING CLINICAL DEMAND FOR ALPHA-BASED RADIOTHERAPIES
6.1.4 RISING CHRONIC DISEASE BURDEN DRIVING RADIOPHARMACEUTICAL DEMAND
6.2 RESTRAINTS
6.2.1 SUPPLY CHAIN AND SCALABILITY CHALLENGES FROM SHORT ISOTOPE HALF-LIVES
6.2.2 STRINGENT REGULATORY LANDSCAPE LIMITING MARKET FLEXIBILITY
6.2.3 SAFETY AND EXPOSURE RISKS IN RADIOPHARMACEUTICAL USE
6.3 OPPORTUNITIES
6.3.1 SURGE IN R&D ACTIVITY EXPANDING RADIOPHARMACEUTICAL APPLICATIONS
6.3.2 EXPANSION OF LU-177-PSMA THERAPY IN PROSTATE CANCER TREATMENT
6.3.3 STRATEGIC COLLABORATIONS DRIVING RADIOPHARMACEUTICAL INNOVATION
6.4 CHALLENGES
6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS
6.4.2 SHORTAGE OF SKILLED WORKFORCE IN NUCLEAR MEDICINE AND RADIOCHEMISTRY
7 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE
7.1 OVERVIEW
7.2 BETA EMITTERS
7.2.1 LUTETIUM-177
7.2.2 TERBIUM-161
7.3 ALPHA EMITTERS
7.3.1 ACTINIUM-225
7.3.2 LEAD -212
8 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES
8.1 OVERVIEW
8.2 REACTOR-PRODUCED ISOTOPES
8.3 GENERATOR-PRODUCED ISOTOPES
8.4 OTHERS
9 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION
9.1 OVERVIEW
9.2 ONCOLOGY
9.2.1 PROSTATE CANCER
9.2.2 NEUROENDOCRINE TUMORS
9.2.3 LIVER CANCER
9.2.4 BRAIN TUMORS
9.2.5 BREAST CANCER
9.2.6 LEUKEMIA
9.3 OTHERS
10 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE
10.1 OVERVIEW
10.2 SMALL MOLECULE LIGANDS
10.3 PEPTIDES
10.4 MONOCLONAL ANTIBODIES
10.5 OTHERS
11 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 ONCOLOGY CENTERS
11.2.2 NUCLEAR MEDICINE DEPARTMENTS
11.3 RADIOPHARMACIES
11.4 RESEARCH INSTITUTES
12 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION
12.1 OVERVIEW
12.2 NORTH AMERICA
12.2.1 U.S.
12.2.2 CANADA
12.2.3 MEXICO
12.3 EUROPE
12.3.1 GERMANY
12.3.2 U.K.
12.3.3 FRANCE
12.3.4 ITALY
12.3.5 SPAIN
12.3.6 POLAND
12.3.7 RUSSIA
12.3.8 NORWAY
12.3.9 TURKEY
12.3.10 AUSTRIA
12.3.11 IRELAND
12.3.12 NETHERLANDS
12.3.13 SWITZERLAND
12.3.14 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 CHINA
12.4.2 AUSTRALIA
12.4.3 JAPAN
12.4.4 SOUTH KOREA
12.4.5 SINGAPORE
12.4.6 INDIA
12.4.7 INDONESIA
12.4.8 PHILIPPINES
12.4.9 THAILAND
12.4.10 MALAYSIA
12.4.11 VIETNAM
12.4.12 TAIWAN
12.4.13 REST OF ASIA-PACIFIC
12.5 SOUTH AMERICA
12.5.1 BRAZIL
12.5.2 ARGENTINA
12.5.3 CHILE
12.5.4 PERU
12.5.5 REST OF SOUTH AMERICA
12.6 MIDDLE EAST AND AFRICA
12.6.1 SOUTH AFRICA
12.6.2 EGYPT
12.6.3 SAUDI ARABIA
12.6.4 U.A.E.
12.6.5 KUWAIT
12.6.6 ISRAEL
12.6.7 REST OF MIDDLE EAST AND AFRICA
13 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: GLOBAL
13.2 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13.3 COMPANY SHARE ANALYSIS: EUROPE
13.4 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 NOVARTIS AG
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 ECKERT & ZIEGLER
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 ITM ISOTOPE TECHNOLOGIES MUNICH SE
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 SHINE TECHNOLOGIES, LLC
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 ACTINIUM PHARMACEUTICALS, INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 PIPELINE PRODUCT PORTFOLIO
15.5.3 RECENT DEVELOPMENTS
15.6 ALPHA TAU MEDICAL LTD.
15.6.1 COMPANY SNAPSHOT
15.6.2 PIPELINE PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 ARICEUM THERAPEUTICS
15.7.1 COMPANY SNAPSHOT
15.7.2 PIPELINE PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 BAYER AG
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PIPELINE PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 CURIUM
15.9.1 COMPANY SNAPSHOT
15.9.2 PIPELINE PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 IONETIX CORPORATION
15.10.1 COMPANY SNAPSHOT
15.10.2 PIPELINE PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 ISOTOPIA
15.11.1 COMPANY SNAPSHOT
15.11.2 PIPELINE PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 LANTHEUS
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PIPELINE PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 LILLY
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PIPELINE PRODUCT PORTFOLIO
15.14 NIOWAVE
15.14.1 COMPANY SNAPSHOT
15.14.2 PIPELINE PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 NMR
15.15.1 COMPANY SNAPSHOT
15.15.2 PIPELINE PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 ONCOINVENT
15.16.1 COMPANY SNAPSHOT
15.16.2 PIPELINE PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 ORANO GROUP
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PIPELINE PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 RADIOPHARM THERANOSTICS LIMITED
15.18.1 COMPANY SNAPSHOT
15.18.2 PIPELINE PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 TELIX PHARMACEUTICALS LIMITED
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PIPELINE PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.2 TERTHERA
15.20.1 COMPANY SNAPSHOT
15.20.2 PIPELINE PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.20.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
표 목록
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
TABLE 5 PENETRATION AND GROWTH PROSPECT MAPPING
TABLE 6 INCIDENCE OF CANCER BY GENDER
TABLE 7 CANCER MORTALITY RATE
TABLE 8 CANCER TREATMENT SUCCESS RATE
TABLE 9 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 10 GLOBAL BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 GLOBAL BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 GLOBAL ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 GLOBAL ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 15 GLOBAL REACTOR-PRODUCED ISOTOPES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 GLOBAL GENERATOR-PRODUCED ISOTOPES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 17 GLOBAL OTHERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 19 GLOBAL ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 GLOBAL ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 GLOBAL OTHERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 23 GLOBAL SMALL MOLECULE LIGANDS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 GLOBAL PEPTIDES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 GLOBAL MONOCLONAL ANTIBODIES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 GLOBAL OTHERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 28 GLOBAL HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 GLOBAL HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 GLOBAL RADIOPHARMACIES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 GLOBAL RESEARCH INSTITUTES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 34 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 35 NORTH AMERICA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 NORTH AMERICA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 38 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 39 NORTH AMERICA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 40 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 42 NORTH AMERICA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 44 U.S. BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 45 U.S. ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 46 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 47 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 48 U.S. ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 51 U.S. HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 53 CANADA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 CANADA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 56 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 57 CANADA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 59 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 60 CANADA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 62 MEXICO BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 MEXICO ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 65 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 66 MEXICO ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 69 MEXICO HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 71 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 72 EUROPE BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 EUROPE ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 75 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 76 EUROPE ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 79 EUROPE HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 80 GERMANY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 81 GERMANY BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 GERMANY ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 GERMANY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 84 GERMANY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 85 GERMANY ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 GERMANY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 GERMANY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 88 GERMANY HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 89 U.K. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 90 U.K. BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 U.K. ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 U.K. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 93 U.K. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 94 U.K. ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 U.K. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 U.K. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 97 U.K. HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 FRANCE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 99 FRANCE BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 FRANCE ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 FRANCE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 102 FRANCE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 103 FRANCE ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 FRANCE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 FRANCE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 106 FRANCE HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 ITALY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 108 ITALY BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 ITALY ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 ITALY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 111 ITALY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 112 ITALY ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 ITALY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 ITALY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 115 ITALY HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 SPAIN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 117 SPAIN BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 SPAIN ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 SPAIN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 120 SPAIN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 121 SPAIN ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 SPAIN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 SPAIN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 124 SPAIN HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 POLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 126 POLAND BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 POLAND ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 POLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 129 POLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 130 POLAND ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 131 POLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 POLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 133 POLAND HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 RUSSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 135 RUSSIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 RUSSIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 RUSSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 138 RUSSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 139 RUSSIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 RUSSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 RUSSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 142 RUSSIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 NORWAY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 144 NORWAY BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 NORWAY ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 NORWAY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 147 NORWAY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 148 NORWAY ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 NORWAY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 NORWAY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 151 NORWAY HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 TURKEY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 153 TURKEY BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 TURKEY ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 TURKEY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 156 TURKEY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 157 TURKEY ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 TURKEY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 TURKEY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 160 TURKEY HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 AUSTRIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 162 AUSTRIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 AUSTRIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 AUSTRIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 165 AUSTRIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 166 AUSTRIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 AUSTRIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 AUSTRIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 169 AUSTRIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 IRELAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 171 IRELAND BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 172 IRELAND ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 173 IRELAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 174 IRELAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 175 IRELAND ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 IRELAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 IRELAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 178 IRELAND HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 NETHERLANDS ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 180 NETHERLANDS BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 NETHERLANDS ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 NETHERLANDS ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 183 NETHERLANDS ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 184 NETHERLANDS ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 NETHERLANDS ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 186 NETHERLANDS ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 187 NETHERLANDS HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 188 SWITZERLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 189 SWITZERLAND BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 SWITZERLAND ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 SWITZERLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 192 SWITZERLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 193 SWITZERLAND ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 SWITZERLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 SWITZERLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 196 SWITZERLAND HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 REST OF EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 198 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 199 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 200 ASIA-PACIFIC BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 ASIA-PACIFIC ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 203 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 204 ASIA-PACIFIC ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 207 ASIA-PACIFIC HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 209 CHINA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 CHINA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 212 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 213 CHINA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 216 CHINA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 218 AUSTRALIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 AUSTRALIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 221 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 222 AUSTRALIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 224 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 225 AUSTRALIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 227 JAPAN BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 JAPAN ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 230 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 231 JAPAN ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 234 JAPAN HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 235 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 236 SOUTH KOREA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 SOUTH KOREA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 239 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 240 SOUTH KOREA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 241 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 242 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 243 SOUTH KOREA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 244 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 245 SINGAPORE BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 SINGAPORE ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 248 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 249 SINGAPORE ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 250 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 252 SINGAPORE HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 254 INDIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 INDIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 257 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 258 INDIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 261 INDIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 263 INDONESIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 264 INDONESIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 266 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 267 INDONESIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 270 INDONESIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 271 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 272 PHILIPPINES BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 PHILIPPINES ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 274 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 275 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 276 PHILIPPINES ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 278 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 279 PHILIPPINES HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 280 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 281 THAILAND BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 THAILAND ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 284 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 285 THAILAND ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 286 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 288 THAILAND HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 289 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 290 MALAYSIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 291 MALAYSIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 292 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 293 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 294 MALAYSIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 295 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 297 MALAYSIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 299 VIETNAM BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 VIETNAM ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 302 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 303 VIETNAM ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 306 VIETNAM HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 308 TAIWAN BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 309 TAIWAN ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 310 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 311 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 312 TAIWAN ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 313 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 314 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 315 TAIWAN HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 316 REST OF ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 317 SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 318 SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 319 SOUTH AMERICA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 SOUTH AMERICA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 321 SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 322 SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 323 SOUTH AMERICA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 326 SOUTH AMERICA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 BRAZIL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 328 BRAZIL BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 329 BRAZIL ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 330 BRAZIL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 331 BRAZIL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 332 BRAZIL ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 333 BRAZIL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 334 BRAZIL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 335 BRAZIL HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 336 ARGENTINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 337 ARGENTINA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 338 ARGENTINA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 339 ARGENTINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 340 ARGENTINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 341 ARGENTINA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 342 ARGENTINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 343 ARGENTINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 344 ARGENTINA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 345 CHILE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 346 CHILE BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 347 CHILE ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 348 CHILE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 349 CHILE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 350 CHILE ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 CHILE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 CHILE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 353 CHILE HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 PERU ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 355 PERU BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 PERU ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 PERU ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 358 PERU ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 359 PERU ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 360 PERU ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 361 PERU ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 362 PERU HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 363 REST OF SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 364 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 365 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 366 MIDDLE EAST AND AFRICA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 367 MIDDLE EAST AND AFRICA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 368 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 369 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 370 MIDDLE EAST AND AFRICA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 371 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 373 MIDDLE EAST AND AFRICA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 374 SOUTH AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 375 SOUTH AFRICA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 376 SOUTH AFRICA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 377 SOUTH AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 378 SOUTH AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 379 SOUTH AFRICA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 380 SOUTH AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 381 SOUTH AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 382 SOUTH AFRICA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 383 EGYPT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 384 EGYPT BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 385 EGYPT ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 386 EGYPT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 387 EGYPT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 388 EGYPT ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 389 EGYPT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 EGYPT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 391 EGYPT HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 392 SAUDI ARABIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 393 SAUDI ARABIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 394 SAUDI ARABIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 395 SAUDI ARABIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 396 SAUDI ARABIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 397 SAUDI ARABIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 398 SAUDI ARABIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 399 SAUDI ARABIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 400 SAUDI ARABIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 U.A.E. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 402 U.A.E. BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 403 U.A.E. ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 404 U.A.E. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 405 U.A.E. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 406 U.A.E. ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 407 U.A.E. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 U.A.E. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 409 U.A.E. HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 410 KUWAIT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 411 KUWAIT BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 KUWAIT ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 413 KUWAIT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 414 KUWAIT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 415 KUWAIT ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 KUWAIT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 KUWAIT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 418 KUWAIT HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 419 ISRAEL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 420 ISRAEL BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 421 ISRAEL ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 ISRAEL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 423 ISRAEL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 424 ISRAEL ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 ISRAEL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 ISRAEL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 427 ISRAEL HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 428 REST OF MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
그림 목록
FIGURE 1 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 2 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: MULTIVARIATE MODELLING
FIGURE 7 CURVE LINE CHART, BY ISOTOPE
FIGURE 8 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 9 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID
FIGURE 10 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: END USER MARKET COVERAGE GRID
FIGURE 12 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 13 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 TWO SEGMENTS COMPRISE THE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 2024
FIGURE 16 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET AND NORTH AMERICA IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 17 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES IS EXPECTED TO DRIVE THE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET IN THE FORECAST PERIOD
FIGURE 18 BETA EMITTERS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET IN 2025 & 2032
FIGURE 19 NORTH AMERICA IS THE FASTEST GROWING REGION FOR THE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET IN 2025 & 2032
FIGURE 20 INCIDENCE BY CANCER SITE
FIGURE 21 CANCER MORTALITY RATE WITH CANCER SITE
FIGURE 22 DROC ANALYSIS
FIGURE 23 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, 2024
FIGURE 24 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 25 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, CAGR (2025-2032)
FIGURE 26 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, LIFELINE CURVE
FIGURE 27 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, 2024
FIGURE 28 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, 2025 TO 2032 (USD THOUSAND)
FIGURE 29 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, CAGR (2025-2032)
FIGURE 30 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, LIFELINE CURVE
FIGURE 31 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, 2024
FIGURE 32 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 33 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, CAGR (2025-2032)
FIGURE 34 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE
FIGURE 35 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, 2024
FIGURE 36 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 37 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, CAGR (2025-2032)
FIGURE 38 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, LIFELINE CURVE
FIGURE 39 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, 2024
FIGURE 40 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 41 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, CAGR (2025-2032)
FIGURE 42 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: SNAPSHOT (2024)
FIGURE 44 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2024 (%)
FIGURE 45 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2024 (%)
FIGURE 46 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2024 (%)
FIGURE 47 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2024 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
